Reactions Weekly

, Volume 1144, Issue 1, pp 4–4 | Cite as

Adjuvant therapy with rituximab appears to be effective but risky in refractory autoimmune bullous skin diseases

Clinical study


Pneumonia Pulmonary Embolism Clinical Response Adjuvant Therapy Blindness 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebeler M.Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. British Journal of Dermatology 156: 352-356, No. 2, Feb 2007Google Scholar

Copyright information

© Adis International limited or Adis Data Information BV 2007

Personalised recommendations